Clinician's Guide to Prevention and Treatment of Osteoporosis

F Cosman, S J de Beur, M S LeBoff, E M Lewiecki, B Tanner, S Randall, R Lindsay, National Osteoporosis Foundation, F Cosman, S J de Beur, M S LeBoff, E M Lewiecki, B Tanner, S Randall, R Lindsay, National Osteoporosis Foundation

Abstract

The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF. Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.

Figures

Fig. 1
Fig. 1
Micrographs of normal vs. osteoporotic bone [9], from Dempster et al., with permission of The American Society for Bone and Mineral Research [9]
Fig. 2
Fig. 2
Pathogenesis of osteoporosis-related fractures, from Cooper and Melton, with modification [10]
Fig. 3
Fig. 3
Z- and T-scores in women, from ISCD Bone Densitometry Clinician Course, Lecture 5 (2008), with permission of the International Society for Clinical Densitometry

References

    1. Office of the Surgeon General (US) (2004) Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General (US), Rockville (MD). Available from: . Accessed March 2014
    1. Wright NC, Looker A, Saag K, Curtis JR, Dalzell ES, Randall S, Dawson-Hughes B (2014) The recent prevalence of osteoporosis and low bone mass based on bone mineral density at the femoral neck or lumbar spine in the United States. J Bone Miner Res. doi: 10.1002/jbmr.2269
    1. Lewiecki EM, Laster AJ. Clinical review: clinical applications of vertebral fracture assessment by dual-energy x-ray absorptiometry. J Clin Endocrinol Metab. 2006;91(11):4215–4222. doi: 10.1210/jc.2006-1178.
    1. Abrahamsen B, van Staa T, Ariely R, Olson M, Cooper C. Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int. 2009;20(10):1633–1650. doi: 10.1007/s00198-009-0920-3.
    1. Colón-Emeric C, Kuchibhatla M, Pieper C, et al. The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporos Int. 2003;11:879–883. doi: 10.1007/s00198-003-1460-x.
    1. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King AB, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007;22(3):465–475. doi: 10.1359/jbmr.061113.
    1. National Committee for Quality Assurance. HEDIS & performance measurement. Proposed changes to existing measure for HEDIS®1 2015: osteoporosis management in women who had a fracture (OMW). Washington, DC. Available at . Accessed 2 March 2014
    1. Khosla S, Riggs BL. Pathophysiology of age-related bone loss and osteoporosis. Endocrinol Metab Clin N Am. 2005;34:1015–1030. doi: 10.1016/j.ecl.2005.07.009.
    1. Dempster DW, Shane E, Horbert W, Lindsay R. A simple method for correlative light and scanning electron microscopy of human iliac crest bone biopsies: qualitative observations in normal and osteoporotic subjects. J Bone Miner Res. 1986;1(1):15–21. doi: 10.1002/jbmr.5650010105.
    1. Cooper C, Melton LJ., 3rd Epidemiology of osteoporosis. Trends Endocrinol Metab. 1992;3(6):224–229. doi: 10.1016/1043-2760(92)90032-V.
    1. Kanis JA, on behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at the primary health care level. Technical Report. World Health Organization Collaborating Center for Metabolic Bone Diseases. University of Sheffield, UK
    1. Tosteson ANA, Melton LJ, 3rd, Dawson-Hughes B, National Osteoporosis Foundation Guide Committee et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int. 2008;19(4):437–447. doi: 10.1007/s00198-007-0550-6.
    1. Dawson-Hughes B, Tosteson ANA, Melton LJ, 3rd, National Osteoporosis Foundation Guide Committee et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the U.S.A. Osteoporos Int. 2008;19(4):449–458. doi: 10.1007/s00198-008-0559-5.
    1. National Osteoporosis Foundation . Health professional’s guide to rehabilitation of the patient with osteoporosis. Washington, DC: National Osteoporosis Foundation; 2003.
    1. American Geriatrics Society, British Geriatrics Society and American Academy of Orthopaedic Surgeons Panel on Falls Prevention Guideline for the prevention of falls in older persons. J Am Geriatr Soc. 2001;49:664–672. doi: 10.1046/j.1532-5415.2001.49115.x.
    1. van den Bergh JP, van Geel TA, Geusens PP. Osteoporosis, frailty and fracture: implications for case finding and therapy. Nat Rev Rheumatol. 2012;8(3):163–172. doi: 10.1038/nrrheum.2011.217.
    1. Watts NB, Adler RA, Bilezikian JP, Endocrine Society et al (2012) Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 97(6):1802–1822. (Also available on the Endocrine Society’s website )
    1. Kanis JA, Melton LJ, 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9(8):1137–1141. doi: 10.1002/jbmr.5650090802.
    1. International Society for Clinical Densitometry. 2013 Official Positions—Adult. . Accessed Feb 2014.
    1. Nelson HD, Haney EM, Chou R, Dana T, Fu R, Bougatsos C (2010) Screening for osteoporosis: systematic review to update the 2002 US Preventive Services Task Force Recommendation. Evidence Syntheses No. 77. AHRQ Publication No. 10-05145-EF-1. Agency for Healthcare Research and Quality, (US), Rockville
    1. Melton LJ, Chrischilles EA, Cooper C, Lane AW, Riggs BL. How many women have osteoporosis? J Bone Miner Res. 2005;20(5):886–892. doi: 10.1359/jbmr.2005.20.5.886.
    1. Lenchik L, Rogers LF, Delmas PD, Genant HK. Diagnosis of osteoporotic vertebral fractures: importance of recognition and description by radiologists. Am J Roentgenol. 2004;183(4):949–958. doi: 10.2214/ajr.183.4.1830949.
    1. Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med. 1991;114(11):919–923. doi: 10.7326/0003-4819-114-11-919.
    1. Schousboe JT, Ensrud KE, Nyman JA, Kane RL, Melton LJ., 3rd Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy. Osteoporos Int. 2005;16(12):1883–1893. doi: 10.1007/s00198-005-1956-7.
    1. Burch J, Rice S, Yang H, Neilson A, Stirk L, Francis R, Holloway P, Selby P, Craig D. Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups. Health Technol Assess (Winchester, England) 2014;18(11):1–206.
    1. National Osteoporosis Foundation . Physician’s guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation; 2005.
    1. National Osteoporosis Foundation (NOF) and International Society for Clinical Densitometry (ISCD). Recommendations to DXA Manufacturers for FRAX® Implementation. Available at . Accessed 28 Jan 2013
    1. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385–397. doi: 10.1007/s00198-007-0543-5.
    1. Larsen ER, Mosekilde L, Foldspang A. Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J Bone Miner Res. 2004;19(3):370–378. doi: 10.1359/JBMR.0301240.
    1. Institute of Medicine (US) Committee to review dietary reference intakes for vitamin D and calcium (2011). In: Ross AC, Taylor CL, Yaktine AL et al (eds) Dietary reference intakes for calcium and vitamin D. National Academies Press (US), Washington (DC). Available from: . Accessed March 2014
    1. Prentice RL, Pettinger MB, Jackson RD, et al. Health risks and benefits from calcium and vitamin D supplementation: Women’s Health Initiative clinical trial and cohort study. Osteoporos Int. 2013;24(2):567–580. doi: 10.1007/s00198-012-2224-2.
    1. Reid IR, Bolland MJ. Calcium supplements: bad for the heart? Heart. 2012;98(12):895–896. doi: 10.1136/heartjnl-2012-301904.
    1. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s Health Initiative limited access dataset and meta-analysis. BMJ. 2011;19:342.
    1. Moyer VA, U.S. Preventive Services Task Force Vitamin D and calcium supplementation to prevent fractures in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;158(9):691–696.
    1. LeBoff MS, Hawkes WG, Glowacki J, Yu-Yahiro J, Hurwitz S, Magaziner J. Vitamin D-deficiency and post-fracture changes in lower extremity function and falls in women with hip fractures. Osteoporos Int. 2008;19(9):1283–1290. doi: 10.1007/s00198-008-0582-6.
    1. Holick MF, Siris ES, Binkley N, et al. Prevalence of vitamin D inadequacy among postmenopausal north American women receiving osteoporosis therapy. J Clin Endocrinol Metab. 2005;90(6):3215–3224. doi: 10.1210/jc.2004-2364.
    1. Looker AC, Pfeiffer CM, Lacher DA, Schleicher RL, Picciano MF, Yetley EA. Serum 25-hydroxyvitamin D status of the US population: 1988–1994 compared to 2000–2004. Am J Clin Nutr. 2008;88(6):1519–1527. doi: 10.3945/ajcn.2008.26182.
    1. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2000;72(3):690–693.
    1. Granacher U, Gollhofer A, Hortobágyi T, Kressig RW, Muehlbauer T. The importance of trunk muscle strength for balance, functional performance and fall prevention in seniors: a systematic review. Sports Med. 2013;43(7):627–641. doi: 10.1007/s40279-013-0041-1.
    1. Sherrington C, Whitney JC, Lord SR, Herbert RD, Cumming RG, Close JC. Effective exercise for the prevention of falls: a systematic review and meta-analysis. J Am Geriatr Soc. 2008;56(12):2234–2243. doi: 10.1111/j.1532-5415.2008.02014.x.
    1. Choi M, Hector M. Effectiveness of intervention programs in preventing falls: a systematic review of recent 10 years and meta-analysis. J Am Med Dir Assoc. 2012;13(2):188.13–188.e21. doi: 10.1016/j.jamda.2011.04.022.
    1. Gillespie LD, Robertson MC, Gillespie WJ, Sherrington C, Gates S, Clemson LM, Lamb SE. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2012;12(9):CD007146.
    1. Gillespie WJ, Gillespie LD, Parker MJ. Hip protectors for preventing hip fractures in older people. Cochrane Database Syst Rev. 2010;10:CD001255.
    1. Ayo-Yusuf OA, Olutola BG. Epidemiological association between osteoporosis and combined smoking and use of snuff among South African women. Niger J Clin Pract. 2014;17:174–177. doi: 10.4103/1119-3077.127542.
    1. Waugh EJ, Lam MA, Hawker GA, McGowan J, Papaioannou A, Cheung AM, et al. Risk factors for low bone mass in healthy 40–60 year old women: a systematic review of the literature. Osteoporos Int. 2009;20:1–21. doi: 10.1007/s00198-008-0643-x.
    1. Benson BW, Shulman JD. Inclusion of tobacco exposure as a predictive factor for decreased bone mineral content. Nicotine Tob Res. 2005;7:719–724. doi: 10.1080/14622200500259119.
    1. Krall EA, Dawson-Hughes B. Smoking increases bone loss and decreases intestinal calcium absorption. J Bone Miner Res. 1999;14:215–220. doi: 10.1359/jbmr.1999.14.2.215.
    1. Maurel DB, Boisseau N, Benhamou CL, et al (2012) Alcohol and bone: review of dose effects and mechanisms. Osteoporos Int 23(1):1–16
    1. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348(9041):1535–1541. doi: 10.1016/S0140-6736(96)07088-2.
    1. Chesnut CH, 3rd, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19(18):1241–1249. doi: 10.1359/JBMR.040325.
    1. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA. 1999;282(14):1344–1352. doi: 10.1001/jama.282.14.1344.
    1. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11(1):83–91. doi: 10.1007/s001980050010.
    1. Kanis JA, Barton IP, Johnell O. Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture. Osteoporos Int. 2005;16(5):475–482. doi: 10.1007/s00198-004-1698-y.
    1. Chesnut CH, 3rd, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000;109(4):267–276. doi: 10.1016/S0002-9343(00)00490-3.
    1. Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282(7):637–645. (Erratum in: JAMA 1999;282(22):2124)
    1. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–765. doi: 10.1056/NEJMoa0809493.
    1. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–1441. doi: 10.1056/NEJM200105103441904.
    1. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799–1809. doi: 10.1056/NEJMoa074941.
    1. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000;85(11):4118–4124. doi: 10.1210/jcem.85.11.6953.
    1. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927–2938. doi: 10.1001/jama.296.24.2927.
    1. Bone HG, Hosking D, Devogelaer JP, Alendronate Phase III Osteoporosis Treatment Study Group et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350(12):1189–1199. doi: 10.1056/NEJMoa030897.
    1. Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res. 2005;20(8):1315–1322. doi: 10.1359/JBMR.050313.
    1. Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis. 2006;65(5):654–661. doi: 10.1136/ard.2005.044958.
    1. Eisman JA, Civitelli R, Adami S, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol. 2008;35(3):488–497.
    1. McClung MR, Geusens P, Miller PD, Hip Intervention Program Study Group et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344(5):333–340. doi: 10.1056/NEJM200102013440503.
    1. Black DM, Delmas PD, Eastell R, HORIZON Pivotal Fracture Trial et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–1822. doi: 10.1056/NEJMoa067312.
    1. Sorensen OH, Crawford GM, Mulder H, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone. 2003;32(2):120–126. doi: 10.1016/S8756-3282(02)00946-8.
    1. Cummings, SR, San Martin J, McClung MR et al (2009) FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. (Erratum in: N Engl J Med. 2009;36(10):191)
    1. Rossouw JE, Anderson GL, Prentice RL, Writing Group for the Women’s Health Initiative Investigators et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333. doi: 10.1001/jama.288.3.321.
    1. Anderson GL, Limacher M, Assaf AR, Women’s Health Initiative Steering Committee et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701–1712. doi: 10.1001/jama.291.14.1775.
    1. Kanis JA, Johansson H, Oden A, Dawson-Hughes B, Melton LJ, 3rd, McCloskey EV. The effects of a FRAX revision for the USA. Osteoporos Int. 2010;21(1):35–40. doi: 10.1007/s00198-009-1033-8.
    1. Ettinger B, Black DM, Dawson-Hughes B, Pressman AR, Melton LJ., 3rd Updated fracture incidence rates for the US version of FRAX. Osteoporos Int. 2010;21(1):25–33. doi: 10.1007/s00198-009-1032-9.
    1. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. NEJM. 1998;339(5):292–299. doi: 10.1056/NEJM199807303390502.
    1. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280(24):2077–2082. doi: 10.1001/jama.280.24.2077.
    1. Eastell R, Devogelaer JP, Peel NF, et al. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int. 2000;11(4):331–337. doi: 10.1007/s001980070122.
    1. U.S. Food and Drug Administration. Reclast (zoledronic acid): drug safety communication—new contraindication and updated warning on kidney impairment. Posted 09/01/2011. Available at: . Accessed 28 Jan 2013
    1. Khosla S, Burr D, Cauley J, American Society for Bone and Mineral Research et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1470–1491. doi: 10.1359/jbmr.0707onj.
    1. Shane E, Burr D, Abrahmsen B, American Society for Bone and Mineral Research et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1–23. doi: 10.1002/jbmr.1998.
    1. Binkley N, Bolognese M, Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C, Buben CE, Gilligan JP, Krause DS, for the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) Investigators A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the oral calcitonin in postmenopausal osteoporosis (ORACAL) trial. J Bone Miner Res. 2012;27(8):1821–1829. doi: 10.1002/jbmr.1602.
    1. Overman RA, Borse M, Gourlay ML. Salmon calcitonin use and associated cancer risk. Ann Pharmacother. 2013;47(12):1675–1684. doi: 10.1177/1060028013509233.
    1. Food and Drug Administration. Questions and answers: changes to the indicated population for miacalcin (calcitonin-salmon). March 11, 2013. Available online:
    1. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007;356:2591–2602. doi: 10.1056/NEJMoa071513.
    1. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat. 2001;65(2):125–134. doi: 10.1023/A:1006478317173.
    1. Martino S, Cauley JA, Barrett-Connor E, CORE Investigators et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004;96(23):1751–1761. doi: 10.1093/jnci/djh319.
    1. Vogel VG, Costantino JP, Wickerham DL, National Surgical Adjuvent Breast and Bowel Project (NSABP) et al. Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727–2741. doi: 10.1001/jama.295.23.joc60074.
    1. Barrett-Connor E, Mosca L, Collins P, Raloxifene Use for The Heart (RUTH) Trial Investigators et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355(2):125–137. doi: 10.1056/NEJMoa062462.
    1. Gennari L, Merlotti D, De Paola V, Martini G, Nuti R. Bazedoxifene for the prevention of postmenopausal osteoporosis. Ther Clin Risk Manag. 2008;4(6):1229–1242.
    1. Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril. 2009;92(3):1045–1052. doi: 10.1016/j.fertnstert.2009.02.093.
    1. Mirkin S, Komm BS, Pan K, Chines AA. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women. Climacteric. 2013;16(3):338–346. doi: 10.3109/13697137.2012.717994.
    1. Pinkerton JV, Pickar JH, Racketa J, Mirkin S. Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention. Climacteric. 2012;15(5):411–418. doi: 10.3109/13697137.2012.696289.
    1. Saag K, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357(20):2028–2039. doi: 10.1056/NEJMoa071408.
    1. Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT) J Bone Miner Res. 2012;27:243–254. doi: 10.1002/jbmr.1494.
    1. Boonen S, Ferrari S, Miller PD. Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk—a perspective. J Bone Miner Res. 2012;27(5):963–974. doi: 10.1002/jbmr.1570.
    1. Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Continuing bisphosphonate treatment for osteoporosis—for whom and for how long? N Engl J Med. 2012;366(22):2051–2053. doi: 10.1056/NEJMp1202623.
    1. Cosman F, Cauley J, Eastell R, Boonen S, Palermo L, Reid I, Cummings SR, Black DM (2014) Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? JCEM (in press)
    1. Bauer DC, Schwartz A, Palermo L, Cauley J, Hochberg M, Santora A, Cummings SR, Black DM (2014) Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern Med 174(7):1126–1134. doi:10.1001/jamainternmed.2014.1232
    1. Bonnick SL. Dual-energy x-ray absorptiometry: interpreting reports and serial measurements. Clin Obstet Gynecol. 2013;56(4):677–685. doi: 10.1097/GRF.0b013e3182a8240c.
    1. Dell R, Greene D. Is osteoporosis disease management cost effective? Curr Osteoporos Rep. 2010;8(1):49–55. doi: 10.1007/s11914-010-0009-0.
    1. McLellan AR, Wolowacz SE, Zimovetz EA, et al. Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int. 2011;22(7):2083–2098. doi: 10.1007/s00198-011-1534-0.
    1. Dell R, Greene D, Schelkun SR, Williams K. Osteoporosis disease management: the role of the orthopaedic surgeon. J Bone Joint Surg Am. 2008;90(Suppl 4):188–194. doi: 10.2106/JBJS.H.00628.
    1. Newman ED. A schema for effective osteoporosis management: outcomes of the Geisinger Health System Osteoporosis Program. Dis Manag Health Outcome. 2003;11(10):611–616. doi: 10.2165/00115677-200311100-00001.
    1. Eisman JA, Bogoch ER, Dell R, Harrington JT, McKinney RE, McLellan A, Mitchell PJ, Silverman S, Singleton R, Siris E, for the ASBMR Task Force on Secondary Fracture Prevention Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res. 2012;27:2039–2046. doi: 10.1002/jbmr.1698.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅